Metabolism of imipramine by microorganisms. 1981

C D Hufford, and G A Capiton, and A M Clark, and J K Baker

The microbial metabolism of imipramine was studied using selected fungal organisms. The major microbial metabolites were isolated, and their structures were established by spectroscopic analyses (particularly 13C-NMR) and by comparison with authentic samples. The microbial metabolites identified included 2-hydroxyimipramine, 10-hydroxyimipramine, iminodibenzyl, imipramine-N-oxide, and desipramine; these metabolites also have been found in mammalian metabolism studies.

UI MeSH Term Description Entries
D007099 Imipramine The prototypical tricyclic antidepressant. It has been used in major depression, dysthymia, bipolar depression, attention-deficit disorders, agoraphobia, and panic disorders. It has less sedative effect than some other members of this therapeutic group. Imidobenzyle,Imizin,4,4'-Methylenebis(3-hydroxy-2-naphthoic acid)-3-(10,11-dihydro-5H-dibenzo(b,f)azepin-5-yl)-N,N-dimethyl-1-propanamine (1:2),Imipramine Hydrochloride,Imipramine Monohydrochloride,Imipramine Pamoate,Janimine,Melipramine,Norchlorimipramine,Pryleugan,Tofranil
D005285 Fermentation Anaerobic degradation of GLUCOSE or other organic nutrients to gain energy in the form of ATP. End products vary depending on organisms, substrates, and enzymatic pathways. Common fermentation products include ETHANOL and LACTIC ACID. Fermentations
D005658 Fungi A kingdom of eukaryotic, heterotrophic organisms that live parasitically as saprobes, including MUSHROOMS; YEASTS; smuts, molds, etc. They reproduce either sexually or asexually, and have life cycles that range from simple to complex. Filamentous fungi, commonly known as molds, refer to those that grow as multicellular colonies. Fungi, Filamentous,Molds,Filamentous Fungi,Filamentous Fungus,Fungus,Fungus, Filamentous,Mold
D001711 Biotransformation The chemical alteration of an exogenous substance by or in a biological system. The alteration may inactivate the compound or it may result in the production of an active metabolite of an inactive parent compound. The alterations may be divided into METABOLIC DETOXICATION, PHASE I and METABOLIC DETOXICATION, PHASE II.

Related Publications

C D Hufford, and G A Capiton, and A M Clark, and J K Baker
February 1981, Journal of pharmaceutical sciences,
C D Hufford, and G A Capiton, and A M Clark, and J K Baker
August 1973, Zhurnal mikrobiologii, epidemiologii i immunobiologii,
C D Hufford, and G A Capiton, and A M Clark, and J K Baker
December 1968, Journal of pharmaceutical sciences,
C D Hufford, and G A Capiton, and A M Clark, and J K Baker
September 1992, British journal of clinical pharmacology,
C D Hufford, and G A Capiton, and A M Clark, and J K Baker
May 1992, Xenobiotica; the fate of foreign compounds in biological systems,
C D Hufford, and G A Capiton, and A M Clark, and J K Baker
January 1973, Journal of agricultural and food chemistry,
C D Hufford, and G A Capiton, and A M Clark, and J K Baker
January 1967, Applied microbiology,
C D Hufford, and G A Capiton, and A M Clark, and J K Baker
May 1967, Applied microbiology,
C D Hufford, and G A Capiton, and A M Clark, and J K Baker
August 1962, Bollettino chimico farmaceutico,
C D Hufford, and G A Capiton, and A M Clark, and J K Baker
January 1961, Medicina experimentalis : International journal of experimental medicine,
Copied contents to your clipboard!